

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2 Revision Date: 07.08.2025 SDS Number: 76201-00029 Date of last issue: 28.09.2024 Date of first issue: 17.03.2015

---

### SECTION 1: IDENTIFICATION

Product name : Grazoprevir / Elbasvir Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : Building A - Level 1/26 Talavera Rd  
Macquarie Park NSW, Australia 2113

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS Classification

Not a hazardous substance or mixture.

#### GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

#### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

---

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	< 10
Grazoprevir	1350462-55-3	< 10
Elbasvir	1370468-36-2	< 10
Magnesium stearate	557-04-0	< 10
Titanium dioxide	13463-67-7	< 1

---

### SECTION 4. FIRST AID MEASURES

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2	Revision Date: 07.08.2025	SDS Number: 76201-00029	Date of last issue: 28.09.2024 Date of first issue: 17.03.2015
----------------	------------------------------	----------------------------	---

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

## SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Metal oxides Chlorine compounds Nitrogen oxides (NO <sub>x</sub> )
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Hazchem Code	: 2Z

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

---

Version 6.2	Revision Date: 07.08.2025	SDS Number: 76201-00029	Date of last issue: 28.09.2024 Date of first issue: 17.03.2015
----------------	------------------------------	----------------------------	---

---

## SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

## SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke.

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version  
6.2

Revision Date:  
07.08.2025

SDS Number:  
76201-00029

Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m3	AU OEL
		TWA	10 mg/m3	ACGIH
Grazoprevir	1350462-55-3	TWA	260 µg/m3 (OEB 2)	Internal
Elbasvir	1370468-36-2	TWA	150 µg/m3 (OEB 2)	Internal
Magnesium stearate	557-04-0	TWA	10 mg/m3	AU OEL
		TWA (Inhal- able particu- late matter)	10 mg/m3	ACGIH
		TWA (Res- pirable par- ticulate mat- ter)	3 mg/m3	ACGIH
Titanium dioxide	13463-67-7	TWA	10 mg/m3	AU OEL

**Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2      Revision Date: 07.08.2025      SDS Number: 76201-00029      Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

---

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder  
Colour : white  
Odour : No data available  
Odour Threshold : No data available  
pH : No data available  
Melting point/freezing point : No data available  
Initial boiling point and boiling range : No data available  
Flash point : Not applicable  
Evaporation rate : Not applicable  
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.  
Flammability (liquids) : No data available  
Upper explosion limit / Upper flammability limit : No data available  
Lower explosion limit / Lower flammability limit : No data available  
Vapour pressure : Not applicable  
Relative vapour density : Not applicable  
Relative density : No data available  
Density : No data available  
Solubility(ies)  
Water solubility : No data available  
Partition coefficient: n-octanol/water : Not applicable  
Auto-ignition temperature : No data available  
Decomposition temperature : No data available

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2      Revision Date: 07.08.2025      SDS Number: 76201-00029      Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

Viscosity  
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics  
Particle size : No data available

---

## SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

## SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation  
Skin contact  
Ingestion  
Eye contact

### Acute toxicity

Not classified based on available information.

### Components:

#### **Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

#### **Grazoprevir:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2      Revision Date: 07.08.2025      SDS Number: 76201-00029      Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

### **Elbasvir:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
LD50 (Mouse): > 1,000 mg/kg

### **Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

### **Titanium dioxide:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Assessment: The substance or mixture has no acute inhalation toxicity

### **Skin corrosion/irritation**

Not classified based on available information.

### **Components:**

#### **Grazoprevir:**

Result : No skin irritation

#### **Elbasvir:**

Species : reconstructed human epidermis (RhE)  
Result : No skin irritation

#### **Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

#### **Titanium dioxide:**

Species : Rabbit  
Result : No skin irritation

### **Serious eye damage/eye irritation**

Not classified based on available information.

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2      Revision Date: 07.08.2025      SDS Number: 76201-00029      Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

### Components:

#### **Grazoprevir:**

Species : Bovine cornea  
Result : No eye irritation

#### **Elbasvir:**

Species : Bovine cornea  
Result : No eye irritation

#### **Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

#### **Titanium dioxide:**

Species : Rabbit  
Result : No eye irritation

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

### Components:

#### **Grazoprevir:**

Test Type : Local lymph node assay (LLNA)  
Exposure routes : Dermal  
Result : Not a skin sensitizer.

#### **Elbasvir:**

Test Type : Local lymph node assay (LLNA)  
Exposure routes : Dermal  
Species : Mouse  
Result : negative

#### **Magnesium stearate:**

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2      Revision Date: 07.08.2025      SDS Number: 76201-00029      Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

### Titanium dioxide:

Test Type : Local lymph node assay (LLNA)  
Exposure routes : Skin contact  
Species : Mouse  
Result : negative

### Chronic toxicity

#### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

##### Grazoprevir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Application Route: Oral  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

##### Elbasvir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Rat  
Application Route: Oral  
Result: negative

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2      Revision Date: 07.08.2025      SDS Number: 76201-00029      Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

**Germ cell mutagenicity - Assessment** : Weight of evidence does not support classification as a germ cell mutagen.

### **Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

### **Titanium dioxide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Mouse  
Result: negative

### **Carcinogenicity**

Not classified based on available information.

### **Components:**

#### **Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

#### **Titanium dioxide:**

Species : Rat  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 2 Years  
Method : OECD Test Guideline 453  
Result : positive  
Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2      Revision Date: 07.08.2025      SDS Number: 76201-00029      Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

### Reproductive toxicity

Not classified based on available information.

#### Components:

##### **Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

##### **Grazoprevir:**

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 400 mg/kg body weight  
Result: negative

Test Type: Multi-generation study  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 400 mg/kg body weight  
Result: No effects on fertility, No effects on foetal development

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight  
Result: No effects on foetal development

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight  
Result: No effects on foetal development

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Intravenous  
Embryo-foetal toxicity: NOAEL: 100 mg/kg body weight  
Result: No effects on foetal development

##### **Elbasvir:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Application Route: Oral

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version  
6.2

Revision Date:  
07.08.2025

SDS Number:  
76201-00029

Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

Fertility: NOAEL: 1,000 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development

: Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight  
Result: No effects on early embryonic development

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight  
Result: No effects on early embryonic development

### **Magnesium stearate:**

Effects on fertility

: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development

: Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### **STOT - single exposure**

Not classified based on available information.

### **STOT - repeated exposure**

Not classified based on available information.

### **Components:**

#### **Grazoprevir:**

Target Organs : Liver, Testis  
Assessment : May cause damage to organs through prolonged or repeated exposure.

### **Repeated dose toxicity**

### **Components:**

#### **Cellulose:**

Species : Rat  
NOAEL : >= 9,000 mg/kg  
Application Route : Ingestion

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2      Revision Date: 07.08.2025      SDS Number: 76201-00029      Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

Exposure time : 90 Days

### Grazoprevir:

Species	:	Rat
NOAEL	:	400 mg/kg
Application Route	:	Oral
Exposure time	:	30 Days
Remarks	:	No significant adverse effects were reported
Species	:	Rat
NOAEL	:	400 mg/kg
Application Route	:	Oral
Exposure time	:	180 Days
Remarks	:	No significant adverse effects were reported
Species	:	Dog
NOAEL	:	15 mg/kg
LOAEL	:	100 mg/kg
Application Route	:	Oral
Exposure time	:	270 Days
Target Organs	:	Liver, Blood, Bone marrow, gallbladder, spleen, Testis
Species	:	Mouse
NOAEL	:	200 mg/kg
LOAEL	:	500 mg/kg
Application Route	:	Oral
Exposure time	:	90 Days
Target Organs	:	Liver, Kidney, Blood
Species	:	Dog
NOAEL	:	20 mg/kg
LOAEL	:	600 mg/kg
Application Route	:	Oral
Exposure time	:	30 Days
Target Organs	:	Blood, Testis
Species	:	Monkey
NOAEL	:	10 mg/kg
Exposure time	:	8 Days
Remarks	:	No significant adverse effects were reported

### Elbasvir:

Species	:	Rat
NOAEL	:	1,000 mg/kg
Application Route	:	Oral
Exposure time	:	180 d
Remarks	:	No significant adverse effects were reported
Species	:	Dog
NOAEL	:	1,000 mg/kg
Application Route	:	Oral

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2      Revision Date: 07.08.2025      SDS Number: 76201-00029      Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

Exposure time : 270 d  
Remarks : No significant adverse effects were reported

### **Magnesium stearate:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

### **Titanium dioxide:**

Species : Rat  
NOAEL : 24,000 mg/kg  
Application Route : Ingestion  
Exposure time : 28 Days

Species : Rat  
NOAEL : 10 mg/m<sup>3</sup>  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 2 yr

### **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

#### **Components:**

##### **Grazoprevir:**

Ingestion : Symptoms: Headache, Gastrointestinal disturbance

##### **Elbasvir:**

Ingestion : Symptoms: Headache, Abdominal pain, constipation, Nausea, Fatigue, muscle pain, joint pain, Dizziness, Cough, Skin irritation, rhinitis, Drowsiness, nasal congestion

---

## **SECTION 12. ECOLOGICAL INFORMATION**

### **Ecotoxicity**

#### **Components:**

##### **Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

##### **Grazoprevir:**

Toxicity to fish : LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10 mg/l

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2	Revision Date: 07.08.2025	SDS Number: 76201-00029	Date of last issue: 28.09.2024 Date of first issue: 17.03.2015
----------------	------------------------------	----------------------------	---

		Exposure time: 96 h Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 10 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
		LC50 (Americamysis): 8.9 mg/l Exposure time: 96 h
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l Exposure time: 72 hrs Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
		NOEC (Pseudokirchneriella subcapitata (green algae)): 10 mg/l Exposure time: 72 hrs Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0.98 mg/l Exposure time: 32 d Method: OECD Test Guideline 210 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 5 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	:	EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
		NOEC: 1.3 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
<b>Elbasvir:</b>		
Toxicity to fish	:	LC50 (Lepomis macrochirus (Bluegill sunfish)): > 10 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility
		LC50 (Menidia beryllina (Silverside)): > 10 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2 Revision Date: 07.08.2025 SDS Number: 76201-00029 Date of last issue: 28.09.2024 Date of first issue: 17.03.2015

---

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility

LC50 (Americamysis): 7.7 mg/l  
Exposure time: 96 h  
Method: US-EPA OPPTS 850.1035  
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (algae)): > 0.081 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.081 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.0023 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.84 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211  
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 271.9 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

**Magnesium stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2      Revision Date: 07.08.2025      SDS Number: 76201-00029      Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction

Remarks: Based on data from similar materials

### **Titanium dioxide:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l

Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

### **Persistence and degradability**

#### **Components:**

##### **Cellulose:**

Biodegradability : Result: Readily biodegradable.

##### **Grazoprevir:**

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 66 %

Exposure time: 28 d

##### **Elbasvir:**

Biodegradability : Result: Not readily biodegradable.

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2      Revision Date: 07.08.2025      SDS Number: 76201-00029      Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

Biodegradation: 37 %  
Exposure time: 28 d

### **Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

### **Bioaccumulative potential**

#### **Components:**

##### **Grazoprevir:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 7.62

Partition coefficient: n-octanol/water : log Pow: 3.72

##### **Elbasvir:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 82  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 6.54

##### **Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

### **Mobility in soil**

#### **Components:**

##### **Grazoprevir:**

Distribution among environmental compartments : log Koc: 4.01

##### **Elbasvir:**

Distribution among environmental compartments : log Koc: 5.24

### **Other adverse effects**

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### **Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2 Revision Date: 07.08.2025 SDS Number: 76201-00029 Date of last issue: 28.09.2024 Date of first issue: 17.03.2015

---

If not otherwise specified: Dispose of as unused product.

---

### SECTION 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Elbasvir)  
Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

##### IATA-DGR

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(Elbasvir)  
Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

##### IMDG-Code

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Elbasvir)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### National Regulations

##### ADG

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Elbasvir)  
Class : 9  
Packing group : III  
Labels : 9  
Hazchem Code : 2Z

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version 6.2      Revision Date: 07.08.2025      SDS Number: 76201-00029      Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

Environmentally hazardous : yes

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

## SECTION 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

Therapeutic Goods (Poisons Standard) Instrument : Schedule 6 (Please use the original publication to check for specific uses, specific conditions or threshold limits that might apply for this chemical)

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

---

## SECTION 16: ANY OTHER RELEVANT INFORMATION

### Further information

Revision Date : 07.08.2025  
Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.  
ACGIH / TWA : 8-hour, time-weighted average  
AU OEL / TWA : Exposure standard - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with

# SAFETY DATA SHEET



## Grazoprevir / Elbasvir Formulation

Version  
6.2

Revision Date:  
07.08.2025

SDS Number:  
76201-00029

Date of last issue: 28.09.2024  
Date of first issue: 17.03.2015

---

x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN